Pharmacological and Safety Profile of Dexlansoprazole: A New Proton Pump Inhibitor – Implications for Treatment of Gastroesophageal Reflux Disease in the Asia Pacific Region

Goh, Khean Lee; Choi, Myung Gyu; Hsu, Ping I.; Chun, Hoon Jai; Mahachai, Varocha; Kachintorn, Udom; Leelakusolvong, Somchai; Kim, Nayoung; Rani, Abdul Aziz; Wong, Benjamin C Y; Wu, Justin C. Y.; Chiu, Cheng‐Tang; Shetty, Vikram; Bocobo, Joseph; Chan, Melchor M.; Lin, Jaw Town

doi:10.5056/jnm15150

Cited by 18 publications

(19 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, of course, the appropriate indications of PPIs therapy should be confirmed as a first step when we decide the potential administration of PPIs. 153,154 When deciding when to administer any medicine, it is important to re-confirm that the beneficial effects will outweigh any potential adverse events. The beneficial therapeutic effects of PPIs for the treatment of GERD, gastroduodenal ulcers, and H. pylori eradication are quite clear, while their effects for symptomatic improvement in patients with functional dyspepsia and for patients with esophageal hypersensitivity are limited.…”

Section: Balancing Advantages and Disadvantages Of Proton Pump Inhibimentioning

confidence: 99%

Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use

Kinoshita

Ishimura

Ishihara

2018

J Neurogastroenterol Motil

187

172

View full text Add to dashboard Cite

Proton pump inhibitors (PPIs) potently inhibit gastric acid secretion and are widely used for treatment of acid-related diseases including gastroesophageal reflux disease and secondary prevention of aspirin/NSAID-induced ulcers. Although clinically important adverse effects of PPIs can occur, just as with other drugs, those are not frequently observed during or after administration. Thus, PPIs are regarded as relatively safe and considered to be clinically beneficial. Recently, PPIs have become frequently administered to patients with functional gastrointestinal diseases or primary prevention of drug-related gastroduodenal damage, even though their beneficial effects for those conditions have not been fully confirmed. PPIs tend to be given for conditions in which the necessity of the drug has not been clarified, thus otherwise rare adverse effects are presented as clinically relevant. Although several PPI-related adverse effects have been reported, their clinical relevance is not yet clear, since the evidence reported in those studies is not at a high enough level, as the majority are based on retrospective observational studies and the reported hazard ratios are low. It is important to administer PPIs only for patients who will gain a substantial clinical benefit and to continue to investigate their adverse effects with high quality prospective studies.

show abstract

Section: Balancing Advantages and Disadvantages Of Proton Pump Inhibimentioning

confidence: 99%

Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use

Kinoshita

Ishimura

Ishihara

2018

J Neurogastroenterol Motil

187

172

View full text Add to dashboard Cite

show abstract

“…GERD impairs the patient's quality of life (QOL) 3 and thus requires appropriate treatment; up to now, medication with protein pump inhibitors (PPIs) has been considered the best therapy. 4,5 The clinical guidelines for GERD published in Korea in 2012, 6 as well as diagnosis and treatment guidelines for GERD published in the United States in 2013, 7 indicate that PPIs are the most effective drugs for the treatment of ERD, with a high level of evidence and a strong level of recommendation. GERD is a complex multifactorial disease, which can be caused by excessive gastroesophageal reflux, reduced esophageal clearance of refluxed gastric contents, increased gastric acid, or increased sensitivity to refluxed contents in the esophageal mucosa.…”

Section: Introductionmentioning

confidence: 99%

A Double-blind, Randomized, Multicenter Clinical Trial Investigating the Efficacy and Safety of Esomeprazole Single Therapy Versus Mosapride and Esomeprazole Combined Therapy in Patients with Esophageal Reflux Disease

Lee

Kim

Cho

et al. 2017

J Neurogastroenterol Motil

View full text Add to dashboard Cite

Background/AimsWe aim to evaluate the efficacy and safety of combination therapy in erosive reflux disease (ERD) patients by comparing endoscopic healing rates according to the Los Angeles classification for esomeprazole alone, and esomeprazole plus mosapride. MethodsA total of 116 ERD patients were randomized to receive esomeprazole 40 mg once daily plus mosapride 5 mg 3 times daily (E+M group), or esomeprazole plus placebo (E only group) for 8 weeks. Patients recorded gastroesophageal reflux disease (GERD) symptom questionnaire at weeks 4 and 8. The primary endpoint was the endoscopic healing rate of ERD after 8 weeks of treatment. ResultsEndoscopic healing rates according to the Los Angeles classification was 32 (66.7%) in the E+M group and 26 (60.5%) in the E only group, but there was no statistically significant difference between the groups. Only at 4 weeks, the total GERD symptom score changes relative to the baseline significantly improved in the E+M group than that of the E only group (-13.4 ± 14.7 vs -8.0 ± 12.3, P = 0.041), and upper abdominal pain and belching score changes showed significantly improved in the E+M group than that of the E only group (P = 0.018 and P = 0.013, respectively). ConclusionsThe combination of a proton pump inhibitor with mosapride shows a tendency for upper abdominal pain, belching, and total GERD symptoms scores to improve more rapidly. This suggests that combination therapy with esomeprazole and mosapride will be useful for rapid improvement of specific GERD symptoms, such as upper abdominal pain and belching in ERD patients.

show abstract

“…Dexlansoprazole, the R-enantiomer of lansoprazole, is comparatively more efficacious [23]. In addition, investigations have shown that it may be taken regardless of meal time schedule [24]. It is metabolized by CYP2C19 and CYP3A4 and is known to interact with atazanavir, nelfinavir, rifampicin, St. John's wort, and fluvoxamine [23,25].…”

Section: Drug-drug Interactionsmentioning

confidence: 99%

“…Dekslanzoprazol, enancjomer R lanzoprazolu, jest relatywnie bardziej skuteczny [23]. Dodatkowo badania wykazały, że może być on przyjmowany niezależnie od pór posiłków [24]. Metabolizowany jest przez CYP2C19 oraz CYP3A4 i wiadomo, że wchodzi w interakcje z atazanawirem, nelfinawirem, ryfampicyną, dziurawcem zwyczajnym oraz fluwoksaminą [23,25].…”

Section: Wskazania Do Stosowania Inhibitorów Pompy Protonowej W Opiecunclassified

See 1 more Smart Citation

Inhibitory pompy protonowej w opiece paliatywnej

Zaporowska-Stachowiak

Oduah

2019

Palliat Med Pract

View full text Add to dashboard Cite

The mainstay of therapy for peptic ulcer disease, gastroesophageal reflux disease (GERD), and Zollinger-Ellison syndrome is the class of medications known as the proton pump inhibitors (PPIs). Omeprazole, the prototype of this group belongs to the chemical class of benzimidazoles; substitution of R groups account for the variation in properties and side-effect profile of the different members of this drug class. The highly potent blocker of gastric acid secretion, this class of medications exerts their effects via a dose-dependent inhibitory action on hydrogen-potassium ATPase proton pump located on the luminal side of the gastric parietal cell. Proton pump inhibitors are mostly indicated in the treatment of chemotherapy induced GERD, in addition, they are first line agents for the treatment of dyspepsia, Helicobacter Pylori eradication, and the prevention and treatment of non-steroidal anti-inflammatory drugs (NSAIDs) and glucocorticosteroid-induced ulcers. There is evidence to support the use of PPIs for treatment of hemoptysis and to limit the incidence of rebleeding palliative patients with peptic ulceration, for metastatic oesophagal and gastric carcinoma. The side effect profiles vary with each drug and there is potential for drug interactions especially in the setting of polypharmacy among palliative care patients. Med Pract 2019; 13, 2: 95-100 Palliat

show abstract

Pharmacological and Safety Profile of Dexlansoprazole: A New Proton Pump Inhibitor – Implications for Treatment of Gastroesophageal Reflux Disease in the Asia Pacific Region

Cited by 18 publications

References 41 publications

Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use

Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use

A Double-blind, Randomized, Multicenter Clinical Trial Investigating the Efficacy and Safety of Esomeprazole Single Therapy Versus Mosapride and Esomeprazole Combined Therapy in Patients with Esophageal Reflux Disease

Inhibitory pompy protonowej w opiece paliatywnej

Contact Info

Product

Resources

About